Cancer patients receiving a certain type of immunotherapy were twice as likely to be alive after three years if they received a COVID-19 mRNA vaccine within 100 days of beginning cancer treatment, new research presented at a recent conference has found. The rest of this article is behind a paywall. Please sign in or subscribe to access the full content.

It was when co-lead researcher Dr Adam Grippin was conducting graduate research at the University of Florida that the idea of using mRNA vaccines to boost the cancer -fighting abilities of the immune system was first mooted.

While developing a personalized mRNA vaccine for brain tumors under the supervision of Dr Elias Sayour, Grippin found that the mRNA vaccine candidates could prime the immune system to eliminate tumors even when t

See Full Page